AB137. SOH21AS049. Audit to evaluate the use of the tumour marker CEA in a level 3 hospital
General Poster Session

AB137. SOH21AS049. Audit to evaluate the use of the tumour marker CEA in a level 3 hospital

Gearoid Murphy, Iayla Fatima

Department of Surgery, St. Luke’s General Hospital, Kilkenny, Ireland

Background: Tumor markers play an important role in cancer cases and their application in practice needs an understanding of its pathophysiology, testing techniques, range of values and their role in any given malignancy. The appropriate use of tumor marker testing is facilitated by national and international guidelines, inappropriate use increases both the laboratory workload and cost. In this study, we evaluated the appropriateness of ordering the tumour marker carcinoembryonic antigen (CEA) in a Model 3 general hospital.

Methods: A single centre retrospective audit was conducted between 1st and 31st October 2020. Patients demographics and admitting consultants details were obtained through HSE online Lab Web Enquiry system. Files were reviewed for indications using the guidelines by the Association of Clinical Biochemists Ireland (ACBI).

Results: A total of 52 tests were ordered over the month, 38 (73.1%) of these tests were ordered correctly following ACBI guidelines. The remaining 14 (26.9%) tests were ordered inappropriately. Fifty percent (26/52) of the total tests were ordered by oncology, 31% (16/52) by General Surgeon and the remaining 19% (10/52) by other specialities. No inappropriate tests were ordered by Oncology, inappropriate tests ordered by General Surgery were 35.7% (5/14) and 64.3% (9/14) by other Specialities.

Conclusions: Nearly 26% of the tests were ordered inappropriately and did not comply with published ACBI guidelines and cost 294 euros. The tumour marker CEA is not useful as the initial work up of nonspecific complaints. Its main use is surveillance after curative resection and for monitoring treatment for patients with advanced colorectal cancer.

Keywords: Carcinoembryonic antigen (CEA); Association of Clinical Biochemists Ireland (ACBI)

Acknowledgments

Funding: None.

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

doi: 10.21037/map-21-ab137
Cite this abstract as: Murphy G, Fatima I. SOH21AS049. Audit to evaluate the use of the tumour marker CEA in a level 3 hospital. Mesentery Peritoneum 2021;5:AB137.

Article Options

Download Citation

Share